We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




PCL Alverno to Implement Beckman Coulter's Expertise

By LabMedica International staff writers
Posted on 25 Feb 2014
PCL Alverno Clinical Laboratories (Hammond, IN, USA) and Beckman Coulter Diagnostics (Brea, CA, USA) announced a partnership to create laboratories to better serve patients. More...
Beckman Coulter was awarded an installation agreement by PLC Alverno with the aim of improving the clinical laboratory.

The contract includes a hematology extension of the laboratory network’s current only source agreement, a new Iris urinalysis agreement, AU chemistry instruments, DxI immunoassay instruments, and four automation lines.

PCL Alverno is a full service, community-based medical laboratory performing over 750 tests in both clinical and anatomic pathology. It is joint venture of two distinct Catholic healthcare systems: Presence Health (IL, USA) and Franciscan Alliance (IN, USA). PCL Alverno provides laboratory services for 26 hospitals in Indiana and Illinois and has a large reference lab for outreach work. Its modern state-of-the-art laboratory is a freestanding, local reference lab in its service area. PCL Alverno offers the personal customer service of a local laboratory with the style of a large reference laboratory. PCL Alverno's pathologists are part of the pathology practice of Pathology Consultants, Inc.

Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. PCL Alverno will modernize their laboratories with more than 150 new instruments beginning in 2014, implementing Beckman Coulter’s automation solutions and expertise in workflow processes.

“We are honored that PCL Alverno has chosen to partner with Beckman Coulter Diagnostics to provide solutions that deliver quality results through automation and standardized workflow processes in the laboratory,” said John Nosenzo, senior vice president of Global Customer Operations, Beckman Coulter Diagnostics. “This partnership demonstrates our shared commitment to patient care and allows us the opportunity to jointly advance and optimize the laboratory—the foundation of patient care.”

Related Links:

PCL Alverno Clinical Laboratories
Beckman Coulter Diagnostics



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Thyroid Test
Anti-Thyroid EIA Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.